Introduction
Evaluation of 1-or 2-level minimally invasive posterior lumbar interbody fusion (MILIF) for degenerative lumbar (DL) disorders in a multicenter 1-year prospective observational study (NCT01143324).
Material and Methods
A total of 252 patients (56% female patients, mean age: 54 years, mean BMI: 28, mean duration of symptoms: 29 months [m]) enrolled by 19 centers in 14 countries underwent 1-(83%) or 2-level (17%) MILIF (TLIF: 95%; PLIF: 5%) for treatment of leg pain (52%), back pain (39%), or claudication (9%) due to DL pathologies, including spondylolisthesis (53%), stenosis (71%), and/or disc pathology (94%). Participating surgeons were required to have a minimum prestudy experience of 30 MILIF cases. A total of 15.1% of patients had previous decompression surgery at the target level. Patient demographics, intraoperative data, complications, time to first ambulation, time to study-defined recovery, surgical duration, blood loss, fluoroscopy time, and adverse events (AEs) were recorded. Outcome scores (VAS back and leg, ODI, EQ-5D) were assessed preoperatively and at defined time points through 12 m postoperatively.
Results
Available for the follow-up: 249 (99%) patients at 4 weeks (w) and 233 (92.5%) at 12 m. One-level surgery occurred at L4-5 or L5-S1 in 91% and 2-level surgery at L4-S1 in 74%. Mean surgical duration, blood loss, and intraoperative fluoro-time were 128 versus 182 minutes, 164 versus 233 mL, and 115 versus 154 seconds in 1-and 2-level cases, respectively. The mean time to first ambulation was 1.3 days and time to study-defined recovery was 3.2 days. Mean preoperative VAS back (6.2) and VAS leg (5.9) scores dropped significantly (p < .0001) to 3.1 (2.9) and 1.9 (2.5) at discharge (4 w), respectively. VAS improvement was sustained between 4 w and final follow-up at 12 m. Fusion rates: 90.8% fusion in 1-and 90.7% for 2-level procedures (141 and 27 patients evaluated, respectively). Preoperative ODI (45.5%) and EQ-VAS (52.9) changed to 34.5% (22.4%) and 65.4 (71.0) at 4 w (12 m) (p < 0.0001). There was a constant improvement in EQ-5D subscales and reduction of pain medication from 4 w to 12 m. A total of 50 AEs in 39 patients (15.5%) were attributed to surgery, approach, or device (including 9 AEs in 8 patients), out of which 3 AEs in 3 patients (1.2%) were due to the minimally invasive approach (including 1 SAE); no deep surgical site infections and 7 reoperations occurred.
